Keyphrases
Psoriasis
100%
Mycosis Fungoides
40%
Moderate-to-severe Psoriasis
30%
Biological Treatment
28%
Ixekizumab
21%
Secukinumab
20%
Scalp
18%
Psoriatic Arthritis
15%
Tertiary Care Hospital
15%
Ustekinumab
14%
Drug Survival
14%
Biologic Therapy
14%
Psoriasis Disease
14%
Psoriasis Severity
13%
Etanercept
13%
Adalimumab
12%
Israeli
12%
Biological Drugs
12%
Hidradenitis Suppurativa
11%
Cutaneous T-cell Lymphoma
11%
Pediatric Psoriasis
11%
Single-center Experience
11%
Risankizumab
11%
Severity Index
10%
Psoriasis Area
10%
Area Index
10%
Glutamatergic Transmission
9%
Psychological Stress
9%
Stress-induced
9%
Retrospective Cohort Study
8%
Systemic Treatment
8%
Confidence Interval
8%
Ultraviolet-B (UV-B)
7%
Skin Diseases
7%
Clinical Data
7%
Anti-TNF Agents
7%
Human Leukocyte Antigen System
7%
Generalized Pustular Psoriasis
7%
IL-17 Inhibitors
7%
Number of Publications
7%
Retrospective Case Series
7%
Meta-analysis
7%
Systemic Therapy
7%
Disease Burden
7%
Hyperpigmented
7%
Plaque Psoriasis
6%
Jewish Patients
6%
Odds Ratio
6%
Dermatology Journals
6%
Hippocampal Slice
6%
Medicine and Dentistry
Psoriasis
67%
Mycosis fungoides
40%
Pediatrics
20%
Dermatology
18%
Biological Product
17%
Scalp
14%
Phototherapy
14%
Ixekizumab
13%
Psoriasis Vulgaris
13%
Systemic Therapy
12%
Secukinumab
12%
Systematic Review
12%
Cutaneous T Cell Lymphoma
11%
Atopic Dermatitis
11%
Risankizumab
11%
Biological Therapy
10%
Adalimumab
10%
Disease
10%
Methotrexate
9%
TNF Inhibitor
9%
Adverse Event
9%
Ustekinumab
8%
Interleukin 17
8%
Dermatosis
8%
Psoriatic Arthritis
8%
Dermatitis
7%
Patient Referral
7%
Generalized Pustular Psoriasis
7%
Exanthem
7%
Nodular Melanoma
7%
Skin Surgery
5%
Inflammatory Bowel Disease
5%
Human Leukocyte Antigen
5%
Patient with Inflammatory Bowel Disease
5%
Skin Cancer
5%
CD8 Antigen
5%
Demodicosis
5%
Prurigo
5%
Papular Rash
5%
Pemphigus
5%
Diagnosis
5%
Psoralen
5%
Population
5%
Vitiligo
5%
Medical Decision Making
5%
Tuberculosis
5%
Retigabine
5%
Health Outcomes
5%
Hypersensitivity
5%
Basal-Cell Carcinoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
91%
Biological Product
24%
Psoriatic Arthritis
14%
Ixekizumab
13%
Secukinumab
13%
Ustekinumab
12%
Risankizumab
11%
Disease
11%
Interleukin 17
10%
Tumor Necrosis Factor Inhibitor
10%
Cohort Study
8%
Etanercept
8%
Methotrexate
8%
Psoriasis Vulgaris
7%
Prevalence
5%
Hepatitis B Virus
5%
Observational Study
5%
Apremilast
5%
Alexithymia
5%
Suppurative Hidradenitis
5%
Cytokine
5%
Hyperthyroidism
5%
Hepatitis C Virus
5%
Hypothyroidism
5%
Retrospective Study
5%
Guselkumab
5%
Tuberculosis
5%
Vismodegib
5%
Rash
5%
Inflammatory Bowel Disease
5%
Basal Cell Carcinoma
5%
Phase IV
5%
Atopic Dermatitis
5%
Mycosis fungoides
5%
Cardiovascular Risk
5%
Survival Rate
5%
Infection
5%